A Risperdal gynecomastia plaintiff was awarded $1.8 million yesterday, after a Pennsylvania jury found that the manufacturers of the antipsychotic medication failed to properly warn patients and doctors about its association with excessive male breast growth. According to court documents, this is the second time this year that a jury has found in favor of a Risperdal plaintiff in the mass tort program currently underway in the Philadelphia Court of Common Pleas.

Johnson & Johnson and its Janssen Pharmaceuticals unit are facing more than 1,500 Risperdal lawsuits that have been filed in Philadelphia on behalf of patients who were allegedly injured by the antipsychotic drug. The just-concluded trial was considered a bellwether case, and was intended to provide some insight into how juries might rule in similar claims involving Risperdal and male breast growth.

Nationwide, the companies are named defendants in more than 5,400 cases filed over Risperdal and its alleged side effects. According to a report from Bloomberg News, Johnson & Johnson acknowledged in a regulatory filing last month that it had established a reserve in regards to this litigation, but the company has not stated the amount set aside specifically for gynecomastia claims.

“We will consider our options going forward,” a Janssen spokesperson told Bloomberg following the announcement of yesterday’s verdict. “Dealing with child psychiatric disorders can be very difficult for families and we sympathize with the plaintiff, Nicholas Murray, and his family.”

Risperdal Gynecomastia Allegations

According to court documents, the plaintiff at the center of this trial began taking Risperdal in 2003, when he was 9-years-old, to treat symptoms associated with autism. At the time, his treatment was considered off-label, as the medication would not be approved for use in autistic children until October 2006. In finding for the now 21-year-old man, the jury determined that Risperdal had been a substantial factor in his excessive breast development.

This is the third time a Pennsylvania jury has rendered a verdict in a Risperdal gynecomastia case this year. In February, the mass tort program’s first bellwether trial concluded with a $2.5 million judgment for another autistic plaintiff who had also been prescribed the drug off-label as a child. Another bellwether case ended the following month, after a second jury found that Johnson & Johnson and Janssen hadn’t properly warned patients and doctors about Risperdal’s link to excessive male breast growth. However, the plaintiff was not awarded any damages because the panel was unable to determine that the drug had actually caused his condition.

Harmed by Risperdal? Obtain Legal Help Today.

The nationwide law firm of Bernstein Liebhard LLP is currently representing a number of plaintiffs who allegedly developed gynecomastia due to their use of Risperdal. If you or a loved one experienced similar complications while taking this medication, please call 1-877-779-1414 to obtain legal assistance with your potential Risperdal lawsuit.

Published November 10, 2015 by